Top 5 Tech Stocks To Buy Right Now

DELAFIELD, Wis. (Stockpickr) -- At Stockpickr, we track daily portfolios of stocks that are the biggest percentage gainers and the biggest percentage losers.

>>5 Big Stocks to Trade for Big Gains

Stocks that are making large moves like these are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility. Stocks that are making big-percentage moves either up or down are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining technical indicators with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

5 Best Consumer Stocks To Invest In 2015: Osiris Therapeutics Inc.(OSIR)

Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, autoimmune, orthopedic, and cardiovascular areas. It operates in two business segments, Therapeutics and Biosurgery. The Therapeutics segment focuses on developing biologic stem cell drug candidates from a readily available and non-controversial source, adult bone marrow. The Biosurgery segment works to harness the ability of cells and novel constructs to promote the body's natural healing. This segment focuses on developing biologic products for use in surgical procedures. The company?s lead biologic drug candidate is Prochymal, which is in phase 2 and 3 clinical trails for various indications, including acute graft versus host disease (GvHD), Crohn's disease, acute myocardial infarction, type 1 diabetes, pulmonary disease, and gastrointestinal injury resulting from radiation exposure. Its biologic drug candidates also include Chondrogen, a preparation of adult mesenchymal stem cells that is in phase 2 clinical trials for osteoarthritis and cartilage protection. The company has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen in various countries except in the United States and Canada. It also has a partnership with Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

Advisors' Opinion:

• [By Lauren Pollock]

  Osiris Therapeutics Inc.(OSIR) said Friday a proposed ruling from the Centers for Medicare and Medicaid Services won’t immediately affect reimbursements for its Grafix stem-cell product. The regenerative medicine company said Grafix will maintain its current reimbursement status — also called transitional pass-through status — potentially through late 2015.

• [By Alexander Maxwell]

  One of the companies attempting to develop a better treatment for chronic diabetic foot ulcers is Osiris Therapeutics� (NASDAQ: OSIR  ) . Earlier this month, Osiris shares more than doubled as the company announced positive data for its CDFU drug Grafix. The study results were very impressive to say the least; the study was stopped early due to the overwhelming efficacy exhibited by the treatment. A main highlight is the fact that 62% of Grafix patients had their wound closed at 12 weeks, compared to only 21% of patients using conventional methods. Clearly, the efficacy in this endpoint was overwhelming. Grafix also achieved all of the secondary endpoints for the trial, and more importantly demonstrated a relatively benign safety record.�

• [By Maxx Chatsko]

  Additionally, stem cell therapies have remained elusive as the industry's ultimate Holy Grail. Osiris (NASDAQ: OSIR  ) received Canadian approval for the world's first stem cell drug, Prochymal, for children battling acute graft-versus-host disease, or GvHD, last year. The approval meant more symbolically than to the bottom line, but it definitely put the potential of stem cells front and center for investors.

Top 5 Tech Stocks To Buy Right Now: CafePress Inc (PRSS)

CafePress Inc. (CafePress), incorporated on October 15, 1999, is an e-commerce platform enabling customers globally to create, buy and sell a range of customized and personalized products. It serves its customers, including both consumers and content owners, through its portfolio of e-commerce Websites, including its Website, CafePress.com. Its consumers include individuals, groups, businesses and organizations. These products include clothing and accessories, art and posters, stickers, home accents and stationery. Its content owners include individual designers, as well as artists and branded content licensors. During the year ended December 31, 2011, it shipped over 7.8 million products from a catalog of over 320 million products. It operates a portfolio of branded Websites, including CafePress.com, and enable resellers and co-branded websites to design and customize products, which target specific consumers, products and use cases, or to provide their customers with product customization capabilities. During 2011, it had nearly 130,000 new images uploaded to its retail e-commerce Websites on average per week. In October 2011, the Company acquired L&S Retail Ventures, Inc. In April 2012, it acquired all of the assets of Logo'd Softwear, Inc. On October 25, 2012, the Company acquired EZ Prints, Inc.

The Company generates revenues from sales of customized products through its e-commerce Websites and associated charges. In addition, it generates revenues from fulfillment services, including print and production services provided to third parties. Consumers purchase customized products directly from Website or through storefronts hosted by CafePress. Customized products include user-designed products, as well as products designed by its content owners. The Company�� services evolved into a platform consist of front-end design and sales channels, and back-end services platform. Its e-commerce Websites and sales channels include CafePress.com, CanvasOnDemand.com, Imagekind.com, GreatBigCanv! as.com, InvitationBox.com, CafePress content owners, branded product manufacturers, other retailers and distributed sales. CanvasOnDemand.com takes photographs and transforms them into canvas artwork. Imagekind.com is where consumers can find artwork by independent artists that can be produced on posters, canvases and framed wall art. GreatBigCanvas.com is a provider of canvas wall art and panoramic canvas photographs. InvitationBox.com is an online provider of stationery products, including invitations, announcements and other products and gifts.

Content owners, including designers, artists, small businesses, groups, clubs and organizations, use the Company�� e-commerce platform to design their own products and sell them through their own hosted e-commerce shop. In addition to such individual content owners, entertainment and publishing companies also license to its materials related to their products for creation of their own shops, online store experiences appearing embedded in their Websites but hosted by it, or for sale directly by it in its marketplaces. By supplying custom design tools and manufacturing services, it enables product manufacturers, such as Sigg and TomTom to offer customized designs on their products. It supplies distributors and resellers with short-run and quick-turn custom printed products. Its back-end services form a platform consisting of the components, which can be used to create front-end buyer and seller experiences, which include user-generated content, licensed fan content, design tools, shops, print/production and fulfillment. Content owners sell their own custom merchandise using its turn-key shops platform, which includes hosting, payment processing, marketing services, fulfillment and customer service. The Company offers users printing on over 600 product stock keeping units (SKUs). It processes and ship orders within three business days after a customer places an order and in many instances can ship orders within 24 hours after an order is placed.

!

Merchandise Assortment

Users visiting one of the Company e-commerce Websites can select from over 600 SKUs of merchandise to customize. Its merchandise catalog includes clothing and accessories, which include t-shirts, sweatshirts, baby products, bags and hats; arts, posters and signs, which include posters, framed art, canvas art, wall decals and signs; stickers and flair, which include stickers, buttons and device cases; home ascents, which include mugs, water bottles and clocks, and stationery, such as business cards, invitations, calendars and journals.

Online Designers

The Company�� portfolio of e-commerce Websites are designed to make product customization simple and easy. Once a product has been selected, users can perform a range of design and editing functions, including uploading their own designs and photos; adding text; adding stock art; scaling and rotating images to fit products; repositioning product elements using conventional and intuitive drag-and-drop functionality; changing fonts or font characteristics, and changing color schemes.

Shops

The Company�� shops platform allows users to sell and market their designed merchandise to their own communities. In addition to customizing the products that they sell, content owners may also customize the look and feel of shops, through which they sell their products. It provides a range of tools to help users market and manage their stores, including basic search engine optimization, e-mail list management and real-time sales reports.

Design, sales and customer service support

The Company is providing customer service, including phone, e-mail and chat support. Its support centers also offer design support to members customizing their own items receive finished products.

The Company competes with Amazon.com, eBay, Etsy, CustomInk, Spreadshirt, Threadless, Zazzle, VistaPrint and Shutterfly.

Advisors' Opinion:

• [By WWW.DAILYFINANCE.COM]

  www.fossil.com From the world's largest retailer stepping up with fresh financials to a maker of fashionable timepieces proving that it can still grow in this unwelcome climate for watchmakers, here are some of the things that will help shape the week that lies ahead on Wall Street. Monday -- Sounds Good DTS (DTSI) has carved a cozy living providing sound-enhancing technology in Blu-ray players, video game consoles and other devices. Despite its success, DTS is trading a lot closer to its 52-week low than its 52-week high. One thing holding it back is that it has failed to impress the market with its quarterly financials. It's coming off back-to-back quarters of falling short of Wall Street's profit expectations. It's against this setting that DTS will step up after Monday's market close to deliver its latest results. Will the streak of disappointment stretch to three quarters, or is DTS finally going to put out a report that looks as good as its audio technology sounds? We will know soon. Tuesday -- Fossil Fuel Fossil (FOSL) may seem to be toiling away in an industry worthy of its name. Aren't wristwatches dinosaurs? Who wears watches anymore when we have smartwatches to tell us the time. Folks with active lifestyles are saving their wrists for fitness bracelets. Well, Fossil is growing just nicely in this environment, thank you very much. When the trendy watchmaker reports on Tuesday analysts see revenue climbing 13 percent. They see top-line growth of 10 percent for all of 2014. Fossil's profitability isn't expected to clock in as nicely, but unlike DTS,we've seen Fossil blow Wall Street's profit targets away consistently over the past year. Wednesday -- Press Hard CafePress (PRSS) has been a disappointment for investors since going public at $19 two years ago. The stock opened higher on its first day of trading, but it's been mostly downhill for the shares, which now fetch less than a third of the initial public offering price. CafePress was hoping

• [By CRWE]

  CafePress Inc. (Nasdaq:PRSS), The World’s Customization EngineTM, reported an expansion of its longstanding partnership with National Geographic, one of the world’s largest nonprofit scientific and educational organizations, with the launch of a new art shop, bringing its legendary photography collection to life on canvas and framed art pieces.

Top 5 Tech Stocks To Buy Right Now: Portola Pharmaceuticals Inc (PTLA)

Portola Pharmaceuticals, Inc. (Portola), incorporated on September 2, 2003, is a biopharmaceutical company developing product candidates that have the potential to represent advances in the fields of thrombosis and hematology. The Company is advancing its three wholly owned programs using biomarker and genetic approaches.

Betrixaban

Portola's compound, betrixaban, is an oral, once-daily Factor Xa inhibitor being evaluated in the only biomarker-based Phase-III study for hospital to home prophylaxis of venous thromboembolism (VTE) in acute medically ill patients. Betrixaban's properties particularly suited to potentially demonstrate efficacy without increasing bleeding in this patient population.

Andexanet Alfa

Portola's second development candidate, andexanet alfa (PRT4445), has the potential to be a reversal agent to directly reverse the effects of Factor Xa inhibitors in patients who suffer a bleeding episode or who require emergency surgery. Portola has entered into clinical collaboration agreements with all of the manufacturers of direct Factor Xa inhibitors, including Bristol-Myers Squibb and Pfizer (Eliquis [apixaban]), Bayer HealthCare and Janssen Pharmaceuticals (XARELTO [rivaroxaban]), and Daiichi Sankyo (Savaysa [edoxaban]), while retaining all decision-making and commercial rights to the program.

Cerdulatinib (PRT2070) and PRT2607

Portola's third wholly owned product candidate, cerdulatinib (PRT2070), is an orally available kinase inhibitor that uniquely inhibits two validated tumor proliferation pathways - spleen tyrosine kinase (Syk) and janus kinase (JAK). It is being studied in patients with leukemias or lymphomas with a focus on genetically-defined subtypes, as well as in patients who have failed therapy due to relapse or acquired mutations. Portola's fourth program is partnered with Biogen Idec and is focused on the development of PRT2607, a selective Syk inhibitor.

Advisors' Opinion:

• [By Todd Campbell]

  That leads me to Medivation (NASDAQ: MDVN  ) , Ophthotech (NASDAQ: OPHT  ) , and Portola (NASDAQ: PTLA  ) , three companies with important therapies that may very well be destined to become top sellers.

Top 5 Tech Stocks To Buy Right Now: Callidus Software Inc.(CALD)

Callidus Software Inc., together with its subsidiaries, provides sales performance management (SPM) software applications and services. Its products include TrueComp Manager application that automates the modeling, design, administration, reporting, and analysis of pay-for-performance programs; Callidus Reporting for delivering real-time production reports; Callidus Analytics, which enable businesses to deploy performance dashboards across the finance, sales executive, and sales force teams; Callidus Objective Management to design and deploy strategic objective-based bonus plans and long term incentive programs; and Callidus Quota Management to allocate quotas effectively. The company?s products also comprise Callidus Communicator, which accelerates and streamlines communications with a business sales force and sales channels; Callidus Channel Management for telecommunication companies to view and update dealer information; Callidus Producer Management for insurance carri ers; Callidus Onboarding to build and optimize discrete, re-usable workflows; Callidus Coaching to optimize performance of their sales force and call centers; Callidus Plan Communicator that accelerates the process of rolling out and communicating incentive plans across the sales force; Callidus Commissions Manager for sales professionals; and ACom3, an incentive compensation automation suite. In addition, it provides software consulting services, including a range of SPM solution implementations, system upgrades, compensation plan enhancements, migration assistance, reporting and integration consulting, and solution architecture services; and SaaS-based sales assessments, coaching, and talent development solutions. The company serves the telecommunications, insurance, banking, technology, and life sciences/pharmaceuticals markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Callidus Software was founded in 1996 and is headquartered in Pleasanton, California.

Advisors' Opinion:

• [By James Oberweis]

  Callidus Software (CALD) is a leading software-as-a-service provider of sales force effectiveness solutions, with more than 1,700 customers.

  Its products help align sales reps' goals with the firm's goals. Since the beginning of 2011, Callidus has dramatically expanded its product offering through the completion of eight acquisitions.

• [By karnacua2]

  Posted-In: Markets Trading Ideas

    Around the Web, We're Loving... Cyber Trading University Presents: The Psychology of a Winning Trader Rumsfeld: Denial of Benefits to Fallen Soldiers' Families 'Inexcusable' Facebook, Baidu Lead Big Caps Beating Shutdown What Should You Know About AMZN? Most Popular These Four Story Stocks Got Beat Up Tuesday (TSLA, LNKD, NFLX, FB) Hewlett Packard's Chromebook 11 Features Innovation Not Found In Apple's MacBook (GOOG, HPQ) UPDATE: J. C. Penney Company, Inc. Provides Update on Progress of Turnaround Yahoo Chose Apple's iPhone, MacBook Pro To Promote Mail Upgrade Apple's iPad 5 Event To Crash Surface Release Party On October 22 Apple Should Have 'Immediately' Apologized For iPhone Blunder Related Articles (CALD) Callidus Software (CALD) Expects Q3 FY2013 Financial Results Will Exceed Previous Guidance, Shares Surged Stocks Hitting 52-Week Highs Morning Market Movers